Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Biomea Fusion (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on developing oral covalent small molecules for diabetes, obesity, and genetically defined cancers, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.

Thomas Butler, CEO and Board Chairman, will deliver a presentation on Wednesday, January 15, 2025, at 1:30 PM PT / 4:30 PM ET. The company's management team will also conduct one-on-one meetings throughout the conference, which runs from January 13 to January 16.

Interested parties can access a live audio webcast of the presentation through the company's investor relations website at investors.biomeafusion.com/news-events/events, with a replay available after the live presentation.

REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced today that Thomas Butler, Chief Executive Officer and Chairman of the Board, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 PM Pacific Time / 4:30 PM Eastern Time. Additionally, Biomea’s management team will be hosting one-on-one meetings throughout the conference, taking place from January 13 to January 16.

A live audio webcast of the presentation can be accessed here or by visiting the Investors & Media section of Biomea’s website at https://investors.biomeafusion.com/news-events/events. A replay of the webcast will be available following the live presentation.

About Biomea Fusion 
Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.  

We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to significantly improve disease treatments for the patients we serve. We aim to cure.  

Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook. 

Contact:  
Ramses Erdtmann  
COO & President of Biomea Fusion 
re@biomeafusion.com  

FAQ

When is Biomea Fusion (BMEA) presenting at the 2025 J.P. Morgan Healthcare Conference?

Biomea Fusion is presenting on Wednesday, January 15, 2025, at 1:30 PM Pacific Time / 4:30 PM Eastern Time.

How can investors watch Biomea Fusion's (BMEA) J.P. Morgan Healthcare Conference presentation?

Investors can watch the live audio webcast through Biomea's investor relations website at investors.biomeafusion.com/news-events/events. A replay will be available after the presentation.

What therapeutic areas does Biomea Fusion (BMEA) focus on?

Biomea Fusion focuses on developing oral covalent small molecules to treat diabetes, obesity, and genetically defined cancers.

What dates will Biomea Fusion (BMEA) be available for one-on-one meetings at the J.P. Morgan conference?

Biomea's management team will be available for one-on-one meetings throughout the conference, from January 13 to January 16, 2025.